These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 14722537)

  • 21. [Development of measles vaccination in Austria].
    Huber EG; Rannon L
    Padiatr Padol; 1973; 8(3):247-56. PubMed ID: 4715034
    [No Abstract]   [Full Text] [Related]  

  • 22. Delayed measles vaccination of toddlers in Canada: Associated socio-demographic factors and parental knowledge, attitudes and beliefs.
    Périnet S; Kiely M; De Serres G; Gilbert NL
    Hum Vaccin Immunother; 2018 Apr; 14(4):868-874. PubMed ID: 29211621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Measles vaccination].
    Gendrel D
    Presse Med; 1993 Sep; 22(28):1299-301. PubMed ID: 8248054
    [No Abstract]   [Full Text] [Related]  

  • 24. Measles, mumps, and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia.
    Aytac S; Yalcin SS; Cetin M; Yetgin S; Gumruk F; Tuncer M; Yurdakok K; Gurgey A
    Pediatr Hematol Oncol; 2010 Aug; 27(5):333-43. PubMed ID: 20469978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measles and pertussis: the timing of vaccination.
    Preston NW
    Lancet; 1995 Apr; 345(8953):858-9. PubMed ID: 7898244
    [No Abstract]   [Full Text] [Related]  

  • 26. [Continuous prophylactic vaccination agains measles].
    László E; Ferenc F; Eva A; Mária S
    Orv Hetil; 1975 May; 116(21):1203-8. PubMed ID: 1128885
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunology series: vaccines.
    Barton LL
    N Engl J Med; 2002 Mar; 346(11):864-6. PubMed ID: 11893804
    [No Abstract]   [Full Text] [Related]  

  • 28. Giant cell pneumonia in a leukemic child in remission: a case report.
    Kanra G; Cetin I; Akçören Z; Cağlar M; Cengiz AB; Baykan A; Kara A
    Turk J Pediatr; 2001; 43(4):338-41. PubMed ID: 11765166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of potentially achievable vaccination coverage of the second dose of measles containing vaccine with simultaneous administration and risk factors for missed opportunities among children in Zhejiang province, east China.
    Hu Y; Chen Y; Wang Y; Liang H
    Hum Vaccin Immunother; 2018 Apr; 14(4):875-880. PubMed ID: 29252094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Humoral immunity to tetanus, measles and rubella in children with acute lymphoblastic leukemia after chemotherapy.
    Onorateli M; Botana C; Peralta L; Rebollo M; Ruvinsky S; Guitter M; Felice MS; Posadas M; Evangelista S; Villar MV; Golluscio M; Molina A; Fraquelli L
    Arch Argent Pediatr; 2016 Dec; 114(6):549-552. PubMed ID: 27869413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Catch-up immunization programs will eliminate measles threat for most schoolchildren.
    Rafuse J
    CMAJ; 1996 May; 154(10):1567-8. PubMed ID: 8625011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal age for vaccinating Nigerian children against measles. II. Seroconversion to measles vaccine in different age groups.
    Ogunmekan DA; Harry TO
    Trop Geogr Med; 1981 Dec; 33(4):379-82. PubMed ID: 7342385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Characteristics of the clinical course of the post-vaccination period and the development of anti-measles immunity in children with allergic diseases].
    Kostinov MP; Balabolkin II; Igna'teva GV; Sadykova DK
    Pediatriia; 1989; (9):33-8. PubMed ID: 2587165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidelines for measles control in Canada.
    Can Dis Wkly Rep; 1991 Feb; 17(7):35-40. PubMed ID: 2029737
    [No Abstract]   [Full Text] [Related]  

  • 35. [Persistence of transplacental immunity against measles. Considerations on the importance of the national immunization program].
    Aceves Saínos D
    Salud Publica Mex; 1976; 18(6):973-80. PubMed ID: 1027142
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of an early two-dose measles vaccination schedule.
    Hutchins SS; Dezayas A; Le Blond K; Heath J; Bellini W; Audet S; Beeler J; Wattigney W; Markowitz L
    Am J Epidemiol; 2001 Dec; 154(11):1064-71. PubMed ID: 11724724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protecting the vaccinating population in the face of a measles epidemic: assessing the impact of adjusted vaccination schedules.
    van den Hof S; Wallinga J; Widdowson MA; Conyn-van Spaendonck MA
    Epidemiol Infect; 2002 Feb; 128(1):47-57. PubMed ID: 11895090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age.
    De Serres G; Boulianne N; Defay F; Brousseau N; Benoît M; Lacoursière S; Guillemette F; Soto J; Ouakki M; Ward BJ; Skowronski DM
    Clin Infect Dis; 2012 Aug; 55(3):394-402. PubMed ID: 22543023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1996 Jul; 45(28):603-6. PubMed ID: 8676852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The measles epidemic in Calgary 1969-70; the protective effect of vaccination for the individual and the community.
    O'Neil AE
    Can Med Assoc J; 1971 Oct; 105(8):819-25. PubMed ID: 5170695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.